Articles

We are proud to announce that the winner of the 2017 ONE Award is Laura Mulderrig, BSN, RN, OCN, a nurse in the clinical research unit at Fox Chase Cancer Center in Philadelphia.

In this issue, we feature a profile of the Taussig Cancer Center, Cleveland Clinic, OH, where, in my capacity as a nurse practitioner in the Department of Hematologic Oncology and Blood Disorders, my primary role is to diagnose and manage patients with multiple myeloma, amyloidosis, and other hematologic disorders.

As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.

To effectively address socioeconomic disparities in healthcare, it is critical that we improve our understanding of the material, psychosocial, and behavioral dimensions of financial well-being, said Reginald D. Tucker-Seeley, MA, ScM, ScD, at the 2017 AACR Science of Cancer Health Disparities Conference.

Although it is very curable when found and treated early on, early-stage cervical cancer may not cause any noticeable signs or symptoms. In advanced stages, however, the disease may cause vaginal bleeding or discharge that is abnormal for the patient.¹

Advocacy usually begins with personal crisis and the need for support, but it eventually moves on to sharing experiences and information with others, speaking out in public forums, and working to influence change, suggested Musa Mayer, breast cancer survivor and advocate, at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal.

The American Academy of Nursing (AAN) released its position statement in recognition that safe nursing practice requires adequate, high-quality sleep to allow them to contribute to patient care safely.

“There’s a human behind the patient, and he can tell us what he needs. He’s really the expert in the field,” Christine B. Boers-Doets, MSc, Netherlands Leiden University Medical Center, told attendees at the recent ESMO International Consensus Conference for Advanced Breast Cancer.

For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase inhibitor in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results presented at the 2017 ESMO Congress.